These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 3152003)

  • 1. Effect of MAO inhibitors on the uptake and metabolism of dopamine in rat and human brain.
    Tekes K; Tóthfalusi L; Gaál J; Magyar K
    Pol J Pharmacol Pharm; 1988; 40(6):653-8. PubMed ID: 3152003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective monoamine oxidase subtype inhibition and striatal extracellular dopamine in the guinea-pig.
    Ilani T; Lamensdorf I; Finberg JP
    Br J Pharmacol; 2000 Aug; 130(8):1992-8. PubMed ID: 10952692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
    Lamensdorf I; Youdim MB; Finberg JP
    J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of MAO inhibitors on the high-affinity reuptake of biogenic amines in rat subcortical regions.
    Tekes K; Magyar K
    Neurobiology (Bp); 2000; 8(3-4):257-64. PubMed ID: 11225517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of monoamine oxidase-B by (-)-deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum.
    Paterson IA; Juorio AV; Berry MD; Zhu MY
    J Pharmacol Exp Ther; 1991 Sep; 258(3):1019-26. PubMed ID: 1679846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Release of endogenous dopamine from rat isolated striatum: effect of clorgyline and (-)-deprenyl.
    Hársing LG; Vizi ES
    Br J Pharmacol; 1984 Nov; 83(3):741-9. PubMed ID: 6439273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition.
    Knoll J; Miklya I
    Arch Int Pharmacodyn Ther; 1994; 328(1):1-15. PubMed ID: 7893186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
    Knoll J
    Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition by deprenyl of dopamine uptake in rat striatum: a possible correlation between dopamine uptake and acetylcholine release inhibition.
    Harsing LG; Magyar K; Tekes K; Vizi ES; Knoll J
    Pol J Pharmacol Pharm; 1979; 31(4):297-307. PubMed ID: 523338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of monoamine oxidase inhibitors on striatonigral dynorphin system: a study with deprenyl and clorgyline.
    Sivam SP
    Neuropeptides; 1993 Jul; 25(1):35-45. PubMed ID: 7692341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of repeated doses of (-) deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgyline.
    Zsilla G; Földi P; Held G; Székely AM; Knoll J
    Pol J Pharmacol Pharm; 1986; 38(1):57-67. PubMed ID: 3020531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. R-(-)-deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron.
    Knoll J
    J Neural Transm Suppl; 1987; 25():45-66. PubMed ID: 2828537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modification of dopamine release by selective inhibitors of MAO-B.
    Finberg JP; Lamensdorf I; Armoni T
    Neurobiology (Bp); 2000; 8(2):137-42. PubMed ID: 11061211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modification of the striatal dopaminergic neuron system by carbon monoxide exposure in free-moving rats, as determined by in vivo brain microdialysis.
    Hara S; Mukai T; Kurosaki K; Kuriiwa F; Endo T
    Arch Toxicol; 2002 Oct; 76(10):596-605. PubMed ID: 12373456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of low-dose treatment with selegiline on dopamine transporter (DAT) expression and amphetamine-induced dopamine release in vivo.
    Lamensdorf I; Porat S; Simantov R; Finberg JP
    Br J Pharmacol; 1999 Feb; 126(4):997-1002. PubMed ID: 10193780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of selective monoamine oxidase (MAO) inhibitors on conditioned avoidance responses (CAR) of rats.
    Timár J; Knoll B; Gyarmati Z; Knoll J
    Pol J Pharmacol Pharm; 1979; 31(4):251-60. PubMed ID: 523335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
    Gal S; Zheng H; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum.
    Butcher SP; Fairbrother IS; Kelly JS; Arbuthnott GW
    J Neurochem; 1990 Sep; 55(3):981-8. PubMed ID: 2117053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in dopamine, serotonin and their metabolites in discrete brain areas of rat offspring after in utero exposure to cocaine or related drugs.
    Henderson MG; McMillen BA
    Teratology; 1993 Nov; 48(5):421-30. PubMed ID: 7508151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats.
    Finberg JP; Wang J; Goldstein DS; Kopin IJ; Bankiewicz KS
    J Neurochem; 1995 Sep; 65(3):1213-20. PubMed ID: 7643100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.